https://scandinavianbiopharma.se/studies/oev-128-phase-iib-study-in-children-6-18-months-in-a-lmic/2026-03-03T12:59:55+00:00https://scandinavianbiopharma.se/studies/study-oev-124-phase-i-descending-age-study-in-a-lmic/2025-10-03T15:14:00+00:00https://scandinavianbiopharma.se/studies/study-oev-123-phase-ii-safety-and-diagnostic-methodology-evaluation/2020-07-01T15:02:23+00:00https://scandinavianbiopharma.se/studies/study-oev-122-phase-i-ii-age-descending-safety-and-immunogenicity-trial-in-a-lmic-age-%e2%89%a56-mo/2020-02-19T15:54:03+00:00https://scandinavianbiopharma.se/studies/study-oev-121a-phase-i-booster-dose-memory-study/2020-02-19T15:54:42+00:00https://scandinavianbiopharma.se/studies/study-oev-121-phase-i-safety-and-immunogenicity-of-vaccine/2020-02-19T15:55:22+00:00https://scandinavianbiopharma.se/studies/study-oev-120-phase-i-safety-and-immunogenicity-of-a-prototype-vaccine/2020-02-19T15:55:56+00:00https://scandinavianbiopharma.se/studies/study-dmid-09-066-phase-i-dmlt-adjuvant-safety-and-immunogenicity/2020-02-19T15:56:17+00:00